Patient-reported problematic symptoms in an ALS treatment trial

Divisha Raheja, Helen E. Stephens, Erik Lehman, Susan Walsh, Chengwu Yang, Zachary Simmons

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study was undertaken to determine which symptoms are perceived to be most problematic for patients with ALS and how their severity changes over time. A retrospective study was performed of data from a randomized, double-blind, placebo-controlled trial of ceftriaxone in ALS. Participants completed the ALS Specific Quality of Life Instrument (ALSSQoL) at baseline and at intervals up to 96 weeks. Ten ALSSQoL items ask participants to rate how problematic symptoms are (the subjective feeling of burden of these symptoms), ranging from 0 (no problem) to 10 (tremendous problem). Six are non-bulbar (pain, fatigue, breathing, strength and ability to move, sleep, and bowel and bladder) and four are bulbar (eating, speaking, excessive saliva, and mucus). Results revealed that there were 82 subjects (56% males, mean age 53 ± 10.3 years) with ALSSQoL data for weeks 0 and 96. All 10 symptoms became more problematic over time. For non-bulbar symptoms, strength/ability to move and fatigue were the most problematic. Speaking was the most problematic bulbar symptom. In conclusion, although all the symptoms in the ALSSQoL were acknowledged as problematic, some had greater impact than others. All became more problematic over time. This should help prioritize research into symptom management, and assist individual clinicians in their approach to patient care.

Original languageEnglish (US)
Pages (from-to)198-205
Number of pages8
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume17
Issue number3-4
DOIs
StatePublished - May 18 2016

Fingerprint

Quality of Life
Aptitude
Fatigue
Ceftriaxone
Mucus
Therapeutics
Saliva
Patient Care
Sleep
Respiration
Emotions
Urinary Bladder
Retrospective Studies
Eating
Placebos
Pain
Research

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Raheja, Divisha ; Stephens, Helen E. ; Lehman, Erik ; Walsh, Susan ; Yang, Chengwu ; Simmons, Zachary. / Patient-reported problematic symptoms in an ALS treatment trial. In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016 ; Vol. 17, No. 3-4. pp. 198-205.
@article{7a2ec87990964c2babe2a2accaed1400,
title = "Patient-reported problematic symptoms in an ALS treatment trial",
abstract = "This study was undertaken to determine which symptoms are perceived to be most problematic for patients with ALS and how their severity changes over time. A retrospective study was performed of data from a randomized, double-blind, placebo-controlled trial of ceftriaxone in ALS. Participants completed the ALS Specific Quality of Life Instrument (ALSSQoL) at baseline and at intervals up to 96 weeks. Ten ALSSQoL items ask participants to rate how problematic symptoms are (the subjective feeling of burden of these symptoms), ranging from 0 (no problem) to 10 (tremendous problem). Six are non-bulbar (pain, fatigue, breathing, strength and ability to move, sleep, and bowel and bladder) and four are bulbar (eating, speaking, excessive saliva, and mucus). Results revealed that there were 82 subjects (56{\%} males, mean age 53 ± 10.3 years) with ALSSQoL data for weeks 0 and 96. All 10 symptoms became more problematic over time. For non-bulbar symptoms, strength/ability to move and fatigue were the most problematic. Speaking was the most problematic bulbar symptom. In conclusion, although all the symptoms in the ALSSQoL were acknowledged as problematic, some had greater impact than others. All became more problematic over time. This should help prioritize research into symptom management, and assist individual clinicians in their approach to patient care.",
author = "Divisha Raheja and Stephens, {Helen E.} and Erik Lehman and Susan Walsh and Chengwu Yang and Zachary Simmons",
year = "2016",
month = "5",
day = "18",
doi = "10.3109/21678421.2015.1131831",
language = "English (US)",
volume = "17",
pages = "198--205",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "3-4",

}

Patient-reported problematic symptoms in an ALS treatment trial. / Raheja, Divisha; Stephens, Helen E.; Lehman, Erik; Walsh, Susan; Yang, Chengwu; Simmons, Zachary.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 17, No. 3-4, 18.05.2016, p. 198-205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient-reported problematic symptoms in an ALS treatment trial

AU - Raheja, Divisha

AU - Stephens, Helen E.

AU - Lehman, Erik

AU - Walsh, Susan

AU - Yang, Chengwu

AU - Simmons, Zachary

PY - 2016/5/18

Y1 - 2016/5/18

N2 - This study was undertaken to determine which symptoms are perceived to be most problematic for patients with ALS and how their severity changes over time. A retrospective study was performed of data from a randomized, double-blind, placebo-controlled trial of ceftriaxone in ALS. Participants completed the ALS Specific Quality of Life Instrument (ALSSQoL) at baseline and at intervals up to 96 weeks. Ten ALSSQoL items ask participants to rate how problematic symptoms are (the subjective feeling of burden of these symptoms), ranging from 0 (no problem) to 10 (tremendous problem). Six are non-bulbar (pain, fatigue, breathing, strength and ability to move, sleep, and bowel and bladder) and four are bulbar (eating, speaking, excessive saliva, and mucus). Results revealed that there were 82 subjects (56% males, mean age 53 ± 10.3 years) with ALSSQoL data for weeks 0 and 96. All 10 symptoms became more problematic over time. For non-bulbar symptoms, strength/ability to move and fatigue were the most problematic. Speaking was the most problematic bulbar symptom. In conclusion, although all the symptoms in the ALSSQoL were acknowledged as problematic, some had greater impact than others. All became more problematic over time. This should help prioritize research into symptom management, and assist individual clinicians in their approach to patient care.

AB - This study was undertaken to determine which symptoms are perceived to be most problematic for patients with ALS and how their severity changes over time. A retrospective study was performed of data from a randomized, double-blind, placebo-controlled trial of ceftriaxone in ALS. Participants completed the ALS Specific Quality of Life Instrument (ALSSQoL) at baseline and at intervals up to 96 weeks. Ten ALSSQoL items ask participants to rate how problematic symptoms are (the subjective feeling of burden of these symptoms), ranging from 0 (no problem) to 10 (tremendous problem). Six are non-bulbar (pain, fatigue, breathing, strength and ability to move, sleep, and bowel and bladder) and four are bulbar (eating, speaking, excessive saliva, and mucus). Results revealed that there were 82 subjects (56% males, mean age 53 ± 10.3 years) with ALSSQoL data for weeks 0 and 96. All 10 symptoms became more problematic over time. For non-bulbar symptoms, strength/ability to move and fatigue were the most problematic. Speaking was the most problematic bulbar symptom. In conclusion, although all the symptoms in the ALSSQoL were acknowledged as problematic, some had greater impact than others. All became more problematic over time. This should help prioritize research into symptom management, and assist individual clinicians in their approach to patient care.

UR - http://www.scopus.com/inward/record.url?scp=84958581036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958581036&partnerID=8YFLogxK

U2 - 10.3109/21678421.2015.1131831

DO - 10.3109/21678421.2015.1131831

M3 - Article

C2 - 26824413

AN - SCOPUS:84958581036

VL - 17

SP - 198

EP - 205

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 3-4

ER -